However, in PTEN-positive prostate and breast cancer cells, loss of integrin α6 or integrin β4 expression leads to a significant decrease in other heterodimeric partners and plectin, while in PTEN-negative cells, the protein levels of heterodimeric partners and plectin are only moderately affected or even upregulated. The gene discussed is PTEN; the disease is breast cancer.